Erratum: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions (Journal of Clinical Investigation (2003) 112 (1506-1520) DOI: 10.1172/JCI200319301);Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

Journal of Clinical Investigation

Volumn 112, Issue 10, 2003, Pages 1506-1520

  Grammer, Amrie C ^a   Slota, Rebecca ^a   Fischer, Randy ^a   Gur, Hanan ^a   Girschick, Hermann ^a   Yarboro, Cheryl ^a   Illei, Gabor G ^a   Lipsky, Peter E ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BG 9588; CD27 ANTIGEN; CD38 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD5 ANTIGEN; CD69 ANTIGEN; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY 5C8; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; CASE REPORT; CELL SUBPOPULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS NEPHRITIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0345824714     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI19301C1     Document Type: Erratum

References (91)

1. Grammer, A.C., Dorner, T., and Lipsky, P.E. 2001. Abnormalities in B cell activity and the immunoglobulin repertoire in human systemic lupus erythematosus. Molecular Pathology of Autoimmune Diseases. 2:282-318.
2. Lipsky, P.E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2:764-766.
3. Grammer, A.C., and Lipsky, P.E. 2002. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 46:1417-1429.
4. Dorner, T., and Lipsky, P.E. 2001. Immunoglobulin variable-region gene usage in systemic autoimmune diseases. Arthritis Rheum. 44:2715-2727.
5. Grammer, A.C., McFarland, R.D., Heaney, J., Darnell, B.F., and Lipsky, P.E. 1999. Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J. Immunol. 163:4150-4159.
6. Dadgostar, H., et al. 2002. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 99:1497-1502.
7. Miyashita, T., et al. 1997. Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions. J. Immunol. 158:4620-4633.
8. Gagro, A., et al. 2003. Naive and memory B cells respond differentially to T-dependent signaling but display an equal potential for differentiation toward the centroblast-restricted CD77/globotriaosylceramide phenotype. Eur. J. Immunol. 33:1889-1898.
9. Gagro, A., et al. 2000. CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology. 101:201-209.
10. Vernino, L.A., Pisetsky, D.S., and Lipsky, P.E. 1992. Analysis of the expression of CD5 by human B cells and correlation with functional activity. Cell. Immunol. 139:185-197.
11. Grammer, A.C., and Lipsky, P.E. 2000. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv. Immunol. 76:61-178.
12. Falini, B., et al. 2003. Expression of the IRTA1 receptor identifies intraepithelial and sub-epithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood. Jul 24. Online publication ahead of print.
13. Dono, M., et al. 2000. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J. Immunol. 164:5596-5604.
14. Su, W., Yeong, K.F., and Spencer, J. 2000. Immunohistochemical analysis of human CD5 positive B cells: mantle cells and mantle cell lymphoma are not equivalent in terms of CD5 expression. J. Clin. Pathol. 53:395-397.
15. Liu, Y.J., and Arpin, C. 1997. Germinal center development. Immunol. Rev. 156:111-126.
16. Choi, Y.S. 1997. Differentiation and apoptosis of human germinal center B-lymphocytes. Immunol. Res. 16:161-174.
17. Mattila, P.S., and Tarkkanen, J. 1997. Age-associated changes in the cellular composition of the human adenoid. Scand. J. Immunol. 45:423-427.
18. Dono, M., et al. 1996. Subepithelial B cells in the human palatine tonsil. I. Morphologic, cytochemical, and phenotypic characterization. Eur. J. Immunol. 26:2035-2042.
19. Medina, F., Segundo, C., Campos-Caro, A., Gonzalez-Garcia, I., and Brieva, J.A. 2002. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 99:2154-2161.
20. + B cell subset with phenotypical characteristics of germinal center B cells. Eur. J. Immunol. 26:1712-1719.
21. Pascual, V., et al. 1994. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180:329-339.
22. Harada, Y., et al. 1996. Identification of early plasma cells in peripheral blood and their clinical significance. Br. J. Haematol. 92:184-191.
23. Bourne, T., Zukowska-Cooper, M., Salaman, M.R., Seifert, M.H., and Isenberg, D.A. 1998. Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38. Clin. Exp. Immunol. 111:611-616.
24. Koarada, S., et al. 1999. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus. Arthritis Rheum. 42:2593-2600.
25. Arce, E., et al. 2001. Increased frequency, of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167:2361-2369.
26. Bijl, M., Horst, G., Limburg, P.C., and Kallenberg, C.G. 2001. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus. 10:866-872.
27. Odendahl, M., et al. 2000. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165:5970-5979.
28. Jacobi, A.M., et al. 2003. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48:1332-1342.
29. Warrington, R.J., Wong, S.K., Ramdahin, S., and Rutherford, W.J. 1995. Normal human cord blood B cells can produce high affinity IgG antibodies to dsDNA that are recognized by cord blood-derived anti-idiotypic antibodies. Scand. J. Immunol. 42:397-406.
30. Han, S., et al. 1995. Cellular interactions in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155:556-567.
31. Qian, J., et al. 2000. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur. J. Immunol. 30:2548-2554.
32. Luzina, I.G., et al. 2001. Spontaneous formation of germinal centers in autoimmune mice. J. Leukoc. Biol. 70:578-584.
33. Vora, K.A., Tumas-Brundage, K.M., and Manser, T. 1998. A periarteriolar lymphoid sheath-associated B cell focus response is not observed during the development of the anti-arsenate germinal center reaction. J. Immunol. 160:728-733.
34. Garside, P., et al. 1998. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 281:96-99.
35. Gray, D., Dullforce, P., and Jainandunsing, S. 1994. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J. Exp. Med. 180:141-155.
36. Arpin, C., et al. 1995. Generation of memory B cells and plasma cells in vitro. Science. 268:720-722.
37. Dono, M., et al. 2001. In vitro stimulation of human tonsillar subepithelial B cells: requirement for interaction with activated T cells. Eur. J. Immunol. 31:752-756.
38. Vinuesa, C.G., et al. 2001. Tracking the response of Xid B cells in vivo: T1-2 antigen induces migration and proliferation but Btk is essential for terminal differentiation. Eur. J. Immunol. 31:1340-1350.
39. Huang, W., et al. 2002. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46:1554-1562.
40. Boumpas, D.T., et al. 2003. A short course of BG9588 (anti-CD40L antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48:719-727.
41. Tan, E.M., et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Micron. 25:1271-1277.
42. Yavuz, S., Grammer, A.C., Yavuz, A.S., Nanki, T., and Lipsky, P.E. 2001. Comparative characteristics of mu chain and alpha chain transcripts expressed by individual tonsil plasma cells. Mol. Immunol. 38:19-34.
43. Dörner, T., Foster, S.J., Farner, N.L., and Lipsky, P.E. 1998. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J. Clin. Invest. 102:688-694.
44. Dorner, T., Heimbacher, C., Farner, N.L., and Lipsky, P.E. 1999. Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythematosus. Clin. Immunol. 92:188-196.
45. Jacobi, A.M., Hansen, A., Burmester, G.R., Dorner, T., and Lipsky, P.E. 2000. Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. Autoimmunity. 33:61-76.
46. Dorner, T., Kaschner, S., Hansen, A., Pruss, A., and Lipsky, P.E. 2001. Perturbations in the impact of mutational activity on Vlambda genes in systemic lupus erythematosus. Arthritis Res. 3:368-374.
47. Cassese, G., et al. 2001. Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31:2726-2732.
48. + and CD5-B cells of patients with systemic lupus erythematosus. J. Clin. Invest. 85:238-247.
49. Facchetti, F., Appiani, C., Salvi, L., Levy, J., and Notarangelo, L.D. 1995. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. J. Immunol. 154:6624-6633.
50. Brezinschek, H.P., Dorner, T., Monson, N.L., Brezinschek, R.I., and Lipsky, P.E. 2000. The influence of CD40-CD154 interactions on the expressed human V(H) repertoire: analysis of V(H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. Int. Immunol. 12:767-775.
51. Monson, N.L., et al. 2001. The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin. Immunol. 100:71-81.
52. Agematsu, K., et al. 1998. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J. Clin. Invest. 102:853-860.
53. Weller, S., et al. 2001. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl. Acad. Sci. U. S. A. 98:1166-1170.
54. Splawski, J.G., and Lipsky, P.E. 1993. CD40-mediated regulation of human B-cell responses. Res. Immunol. 145:226-237.
55. Nishioka, Y., and Lipsky, P.E. 1994. The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration. J. Immunol. 153:1027-1036.
56. McCarty, G.A., Rice, J.R., Bembe, M.L., and Pisetsky, D.S. 1982. Independent expression of autoantibodies in systemic lupus erythematosus. J. Rheumatol. 9:691-695.
57. Perez, M.C., Wilson, W.A., and Scopelitis, E. 1989. Cyclophosphamide use in a young woman with antiphospholipid antibodies and recurrent cerebrovascular accident. South. Med. J. 82:1421-1424.
58. Ginsburg, W.W., Finkelman, F.D., and Lipsky, P.E. 1978. Circulating and mitogen-induced immunoglobulin-secreting cells in human peripheral blood: evaluation by a modified reverse hemolytic plaque assay. J. Immunol. 120:33-39.
59. Jelinek, D.F., and Lipsky, P.E. 1983. The role of B cell proliferation in the generation of immunoglobulin-secreting cells in man. J. Immunol. 130:2597-2604.
60. Vernino, L., McAnally, L.M., Ramberg, J., and Lipsky, P.E. 1992. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated anti-CD3-activated T cells. J. Immunol. 148:404-410.
61. Grammer, A.C., et al. 1995. The CD40 ligand expressed by human B cells costimulates B cell responses. J. Immunol. 154:4996-5010.
62. Lipsky, P.E., Attrep, J.F., Grammer, A.C., McIlraith, M.J., and Nishoka, Y. 1997. Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Ann. N. Y. Acad. Sci. 815:372-383.
63. Shinozaki, K., Yasui, K., and Agematsu, K. 2001. Direct B/B-cell interactions in immunoglobulin synthesis. Clin. Exp. Immunol. 124:386-391.
64. Brams, P., et al. 2001. A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int. Immunopharmacol. 1:277-294.
65. + T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB × NZW)F1 lupus-prone mice: phenotype and possible role in autoreactivity. J. Immunol. 165:4095-4104.
66. Santos-Argumedo, L., Alvarez-Maya, I., Romero-Ramirez, H., and Flores-Romo, L. 2001. Enforced and prolonged CD40 ligand expression triggers autoantibody production in vivo. Eur. J. Immunol. 31:3484-3492.
67. Higuchi, T., et al. 2002. Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. Immunol. 168:9-12.
68. Krzysiek, R., et al. 2000. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood. 96:2338-2345.
69. Henn, V., Steinbach, S., Buchner, K., Presek, P., and Kroczek, R.A. 2001. The inflammatory action of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 98:1047-1054.
70. Hermann, A., Rauch, B.H., Braun, M., Schror, K., and Weber, A.A. 2001. Platelet CD40 ligand (CD40L): subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 12:74-82.
71. Schwarz, U.R., Kobsar, A.L., Koksch, M., Walter, U., and Eigenthaler, M. 2000. Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. Biochem. Pharmacol. 60:1399-1407.
72. Slupsky, J.R., et al. 1998. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb. Haemost. 80:1008-1014.
73. Henn, V., et al. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:591-594.
74. Schonbeck, U., and Libby, P. 2001. CD40 signaling and plaque instability. Circ. Res. 89:1092-1103.
75. Bruemmer, D., et al. 2001. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am. J. Cardiol. 87:21-27.
76. Hakkinen, T., Karkola, K., and Yla-Herttuala, S. 2000. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch. 437:396-405.
77. Lienenluke, B., Germann, T., Kroczek, R.A., and Hecker, M. 2000. CD154 stimulation of interleukin-12 synthesis in human endothelial cells. Eur. J. Immunol. 30:2864-2870.
78. Kotowicz, K., Dixon, G.L., Klein, N.J., Peters, M.J., and Callard, R.E. 2000. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology. 100:441-448.
79. Thienel, U., Loike, J., and Yellin, M.J. 1999. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell. Immunol. 198:87-95.
80. Jollow, K.C., Zimring, J.C., Sundstrom, J.B., and Ansari, A.A. 1999. CD40 ligation induced phenotypic and functional expression of CD80 by human cardiac microvascular endothelial cells. Transplantation. 68:430-439.
81. Schonbeck, U., et al. 1999. Expression of stromelysin-3 in lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. 189:843-853.
82. Slupsky, J.R., et al. 1998. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb. Haemost 80:1008-1014.
83. Zhou, L., et al. 1998. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb. Haemost. 79:1025-1028.
84. Dechaner, J., et al. 1997. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J. Immunol. 159:5640-5647.
85. Miller, D.L., Yaron, R., and Yellin, M.J. 1998. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol. 63:373-379.
86. Mach, F., et al. 1997. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 94:1931-1936.
87. Karmann, K., Min, W., Fanslow, W.C., and Pober, J.S. 1996. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J. Exp. Med. 184:173-182.
88. Hollenbaugh, D., et al. 1995. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182:33-40.
89. Karmann, K., Hughes, C.C., Schechner, J., Fanslow, W.C., and Pober, J.S. 1995. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. U. S. A. 92:4342-4346.
90. Davis, J.C., Jr., Totoritis, M.C., Rosenberg, J., Sklenar, T.A., and Wofsy, D. 2001. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 28:95-101.
91. Kalunian, K.C., et al. 2002. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:3251-3258.